StoneX Group’s Ionis Pharmaceuticals IONS Stock Holding History

StoneX Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,748	Closed	-$598K	–	256
2017 Q2	$598K	Buy	+11,748	New	+$547K	0.19%	184

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

StoneX Group's IONS Position: Q3 2017 in Review

StoneX Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 11,748 shares — an estimated $598K sold.

StoneX Group first reported a position in IONS in Q2 2017 and held it in 1 quarter. The position peaked at $598K in Q2 2017. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

StoneX Group reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
StoneX Group sold 11,748 Ionis Pharmaceuticals shares in Q3 2017, an estimated $598K.
StoneX Group first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 1 quarter.
StoneX Group's Ionis Pharmaceuticals position peaked at $598K in Q2 2017.
301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on StoneX Group's 13F filing for Q3 2017, filed 13 Nov 2017.